Pathogen-specific recombinant human polyclonal antibodies: biodefence applications (Q35684876)

9 August 2017

1 reference

title

Pathogen-specific recombinant human polyclonal antibodies: biodefence applications (English)

1 reference

9 August 2017

Søren Bregenholt

1

1 reference

9 August 2017

John Haurum

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Biological Therapy

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

387-396

1 reference

The antiviral activity of antibodies in vitro and in vivo.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

The looming threat of bioterrorism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Antibodies for defense against biological attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Passive antibody administration (immediate immunity) as a specific defense against biological weapons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Intravenous immunoglobulin: regulatory perspectives on use and supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Recombinant polyclonal antibody libraries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Evaluation of 21st-century risks of smallpox vaccination and policy options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

21 January 2018

Bacterial superantigens

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Threats in bioterrorism. I: CDC category A agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Search for correlates of protective immunity conferred by anthrax vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Human antibodies from immunized donors are protective against anthrax toxin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Botulinum Toxin as a Biological Weapon: Medical and Public Health Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Smallpox as a Biological Weapon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Pathogenesis and potential antiviral therapy of complications of smallpox vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Neutralizing and protective antibodies directed against vaccinia virus envelope antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Phage antibodies neutralize vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Tularemia as a biological weapon: medical and public health management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Hemorrhagic fever viruses as biological weapons: medical and public health management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Elevated levels of total and dengue virus-specific immunoglobulin E in patients with varying disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Human asymptomatic Ebola infection and strong inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Early immune responses accompanying human asymptomatic Ebola infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Epitopes involved in antibody-mediated protection from Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Human recombinant neutralizing antibodies against hantaan virus G2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Threats in bioterrorism. II: CDC category B and C agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

In vitro mechanisms of monoclonal antibody neutralization of alphaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Severe acute respiratory syndrome--a new coronavirus from the Chinese dragon's lair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

The continued pandemic threat posed by avian influenza viruses in Hong Kong.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

Biodefence on the research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.3.387

21 January 2018

Identifiers

DOI

10.1517/14712598.4.3.387

1 reference

9 August 2017

1 reference